Guardian Investigate launch puts Cellebrite DI (CLBT) in focus
Cellebrite DI (NasdaqGS:CLBT) is drawing fresh attention after launching Guardian Investigate worldwide, an AI-powered case management tool designed to help law enforcement teams organize, analyze and collaborate on complex digital investigations.
See our latest analysis for Cellebrite DI.
The Guardian Investigate launch comes after a mixed period for the stock, with a 1-day share price return of 2.16% to US$13.23, a 90-day share price return showing a 26.46% decline, and a 3-year total shareholder return of 122.35%. This suggests longer term holders have still seen strong gains even as recent momentum has faded.
If AI driven law enforcement tools interest you, it can be useful to see what else is on the market and compare with 34 AI small caps
With Guardian Investigate now rolled out globally and Cellebrite posting annual revenue of US$475.675m and net income of US$77.813m, the key question is whether the current US$13.23 share price reflects fair value or if the market is already pricing in future growth.
Most Popular Narrative: 38.9% Undervalued
The most followed narrative pegs Cellebrite DI’s fair value at $21.67, well above the last close at $13.23, and ties that gap directly to long range growth expectations and richer earnings multiples.
The continued transition to a recurring, subscription-based revenue model, with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration, improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.
Curious how that recurring revenue story feeds into the $21.67 fair value, the projected earnings step up, and a future P/E above typical software names, the full narrative spells out the exact growth, margin and valuation assumptions behind that gap to today’s price.
Result: Fair Value of $21.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story also leans on risks, including reliance on US federal contracts and fast moving mobile security that could pressure growth, margins, and valuations.
Find out about the key risks to this Cellebrite DI narrative.
Another View on Valuation
The earlier narrative leans on future earnings and a premium P/E to argue Cellebrite DI is undervalued. However, the current P/E of 42.4x is well above the US Software industry at 28.2x and the fair ratio of 28.1x. This points to meaningful valuation risk if sentiment cools.
Peers on average trade at a P/E of 45.3x, so Cellebrite sits slightly below that group while still well above both industry and fair ratio anchors. This raises a simple question for investors: is this pricing a reasonable premium for quality, or a margin of safety that is too thin?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mix of optimism and caution in this story feels familiar, act while the details are still fresh and shape your own view with the 4 key rewards
Looking for more investment ideas?
Do not stop at a single stock when there is a whole market of opportunities to compare, stress test, and put in context using focused screeners.
- Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 62 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies with higher yields using the 12 dividend fortresses.
- Prioritize resilience and peace of mind by filtering for companies with steadier profiles via the 62 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com